Immunoglobulin trial for Alzheimer’s discontinued
May 9, 2013
Baxter International Inc. officials said its Phase III clinical study of immunoglobulin did not reduce cognitive decline in those with moderate Alzheimer’s. (UPI)
May 9, 2013
Baxter International Inc. officials said its Phase III clinical study of immunoglobulin did not reduce cognitive decline in those with moderate Alzheimer’s. (UPI)